Larimar Therapeutics, Inc.
LRMR
$0.03
Change (1 day)
$13.68
Year High
$3.01
Year Low
Categories
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Stock split history for Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. stock (symbol: LRMR) underwent a total of 1 stock splits.
The most recent stock split occured on May 29, 2020.
Annual Revenue
| Date | Splite | Multiple |
|---|---|---|
| 2020-05-29 | 1:12 | 1 |